Updated EPO Guidelines on AI – why US companies should encourage close collaboration between their US and European attorneys on AI patent applications

​
Joel Todd
​
Felix Hall
​
May 20, 2024

On 1 March 2024, the European Patent Office (EPO) updated its Guidelines for Examination regarding AI inventions. This included new wording relating to the sufficient disclosure of training data.

Specifically, the new Guidelines state in F-III-3 that there may be insufficiency in the invention where "the mathematical methods and the training datasets are disclosed in insufficient detail to reproduce the technical effect over the whole range claimed. Such a lack of detail may result in a disclosure that is more like an invitation to a research programme"; and in G-II-3.3.1 that "the technical effect that a machine learning algorithm achieves may be readily apparent or established by explanations, mathematical proof, experimental data or the like. While mere allegations are not enough, comprehensive proof is not required either. If the technical effect is dependent on particular characteristics of the training dataset used, those characteristics that are required to reproduce the technical effect must be disclosed unless the skilled person can determine them without undue burden using common general knowledge. However, in general, there is no need to disclose the specific training dataset itself".

Since then, we have become aware of commentary from US practitioners suggesting that these updates introduce "ambiguity" to the disclosure requirements that will make US applicants unsure whether it is even worth filing AI related patent applications at the EPO.

However, from a European patent attorney's perspective, these new sections represent a relatively straightforward application of established EPO principles of sufficiency to AI inventions. For sufficiency, what matters is whether the skilled person, with their common general knowledge, has enough information to carry out the invention without undue burden (see e.g. F-III-1 of the Guidelines, as well as II-4.1 of the Case Law of the Boards of Appeal); this guidance has existed in the Guidelines since at least 2001 (see C-II-4.9 of the 2001 Guidelines). As applied to AI, the skilled person needs to know, or be able to determine without undue burden, the characteristics of the training data required to produce the technical effect. If the training data is standard, which it very often is, then not much will be needed, whereas if there is something special about the training data or how it is collected, then more detailed steps of data collection, or alternatively a publicly available dataset, should be provided.

In our opinion, it therefore seems at least some of the suggested "ambiguity" in the new Guidelines may have more to do with a lack of familiarity with longstanding European patent practice, than with an inherent ambiguity in the update itself.

Our conclusion is not that US companies should avoid filing in Europe, but that close collaboration between their European and US patent attorneys is to be encouraged to optimise the specification for both jurisdictions. With our experienced team of European and US patent attorneys working together, EIP is particularly well placed to help clients get the best protection possible for their AI inventions, globally.

Recent Case Reports

Bringing enforcement proceedings while an appeal is still pending risks liability for defendant’s costs
24 September 2026
The Court of Appeal held that setting aside a first-instance decision granting relief subject to recurring penalties generally has retroactive effect. Any penalty fees already paid will be refunded by the Court. The value of proceedings is determined by the interest of the party that brought the action. This is not changed as a result of an appeal. A claimant bringing enforcement proceedings while an appeal is still pending does so at its own risk and may be liable for the defendant’s costs related to the enforcement proceedings.‍
Unsigned Appeal Rejected as Inadmissible
24 September 2026
The Court of Appeal held that a statement of appeal that is not electronically signed is not validly lodged under Rule 4.1 RoP, and that this defect cannot be cured after expiry of the non-extendable appeal period. The appeal was therefore rejected as inadmissible, and a late application for re-establishment of rights was itself held to be out of time.
Scripps mRNA reengineering patent found invalid and not infringed by Comirnaty
08 September 2026
The Local Division Munich invalidated Promosome's licensed mRNA patent over Scripps' codon-optimisation method, then found BioNTech's Comirnaty vaccine would not have infringed the claims even had they been valid.